Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT04975464 |
| Other study ID # |
11-3393 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
November 15, 2011 |
| Est. completion date |
December 2021 |
Study information
| Verified date |
July 2021 |
| Source |
Hennepin Healthcare Research Institute |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
In this study, the investigators will be looking at results of tests of memory and thinking
and daily activities in a group of people without known chronic kidney disease (CKD) , and a
group of CKD patients, and follow the participants for up to four more years, including after
the participants start dialysis or receive a transplant. The investigators are doing this
study to compare how often memory loss, confusion and difficulty with daily activities occur
in those without and those with CKD. Additionally, the investigators are doing this study to
identify risk factors for memory and thinking problems in CKD patients. The information
received through the NDI will be utilized to help track our study population and help provide
useful information regarding cause of death of those in our study.
Description:
Cognitive impairment (CI) in patients with pre-dialysis chronic kidney disease (CKD) is
common, affecting more than five million older people with moderate to severe CKD (estimated
glomerular filtration rate-eGFR < 45). Both lower eGFR and increased albuminuria, a marker of
systemic vascular endothelial function, are associated with increased dementia risk and
structural MRI changes. Stroke prevalence is four times higher in advanced CKD than in
non-CKD, and white matter hyperintensity (WMH) volume and cerebral atrophy are increased.
Yet, the natural history, contributing factors, and brain abnormalities associated with
cognitive decline in CKD are poorly understood. In addition, previous studies of CI in CKDthe
investigators such as ADNI primarily included patients with mild CKD and lower risk of CI,
and few have included longitudinal measures of CI. To fill these gaps, our multidisciplinary
team (geriatrics, neurology, nephrology, neuroimaging) initiated the longitudinal BRain IN
Kidney (BRINK) disease study. The investigators assembled a unique cohort of 433 CKD patients
(~20% mild-moderate; 35% advanced; 45% severe; eGFR < 30), with mean eGFR of 34, and 141
non-CKD (eGFR ≥ 60) controls, followed the participants for a median of 2.5 years, and
obtained baseline brain MRI, serial cognitive testing, and serum and urine biomarkers. Our
primary goal is to extend BRINK and obtain three and five year brain MRIs to characterize
cognitive decline and Alzheimer's disease and cerebrovascular-related MRI brain changes over
five years. The investigators propose that CKD and its brain sequelae represent a model of
accelerated cerebrovascular disease and brain aging, with high rates of hypertension (> 90%),
diabetes (50%), inflammation, and oxidative stress-all factors known to contribute to both
vascular dementia and Alzheimer's disease-driving parallel trajectories of microvascular
endothelial dysfunction in the kidney and brain and secondary neurodegeneration. Our
preliminary data demonstrate that at baseline those with eGFR < 30 compared to eGFR ≥ 30 were
almost twice as likely to have moderate-severe CI, and delayed memory was most affected, as
seen in Alzheimer's disease. On brain MRI, the participants also had more strokes, WMH, and
worse white matter integrity. In addition, the investigators found that the common
CKD-related factors of elevated serum phosphorus and low hemoglobin were associated with
worse cognitive function and more severe abnormalities on brain MRI. Our cross-sectional MRI
findings support a cerebrovascular basis for CI in CKD, accelerated by CKD-related factors,
together driving neurodegenerative changes that may serve as a proximate correlate of CI in
CKD. Driven by our initial findings, the investigators seek to extend BRINK to define the
relation between CKD severity and worsening MRI changes and cognitive decline, and the
relation between the two. In addition, as the COVID pandemic has accelerated within the US
with associated cerebrovascular, cognitive and CKD outcomes, the investigators will leverage
this period to examine the effects of COVID diagnosis, symptoms and outcomes on cognitive
decline and CKD progression. The investigators will measure these associations using a new
COVID survey modeled after the COVID Symptom Tracker from Harvard. Specifically, the
investigators propose the following longitudinal aims:
SPECIFIC AIMS (Note: all models will be adjusted for time-varying and time-invariant
covariates) Aim 1 (total cohort): Characterize longitudinal changes in level of global
cognitive function and cognitive domains over a mean of five years by eGFR level and examine
COVID - 19 exposure as potential interaction.
Hypotheses 1: Those with eGFR < 30 will be at greater risk of developing moderate/severe CI
and decline in cognitive domain scores.
Aim 1a (CKD only): Estimate the associations between change in CKD-related factors and change
in cognitive function in CKD over a mean of five years. Hypothesis 1a: Worsening CKD-related
factors will be significantly associated with decline in global cognition and decline in
cognitive domain scores.
Hypothesis 1b: COVID-19 exposure may modify and accelerate the relation between CKD
progression and cognitive decline.
Aim 2 (MRI cohort): Determine the rate of cortical thinning, accumulation of WMHs, infarcts,
change in WM integrity, and perfusion by eGFR levels over a mean of five years. Hypothesis 2:
Frontotemporal cortical thinning (atrophy), increased cortical infarcts and WMH volume, and
especially decreased global white matter integrity will progress more quickly with lower eGFR
level.
Aim 2a (MRI cohort): Estimate the associations between CKD-related factors and structural and
functional MRI changes over a mean of five years. Hypothesis 2a: Low hemoglobin and higher
albuminuria will be associated with increased cortical thinning and decreased white matter
integrity, and higher phosphorus with increased infarcts.
Aim 3 (MRI cohort): Measure the association between changes in structural and functional MRI
and cognitive decline over a mean of five years. Hypothesis 3: Cortical thinning, increased
WMH, infarcts, and worsening WM integrity and will be associated with decline in global
cognition and cognitive domain scores.
This study is innovative by: a) mapping the longitudinal trajectories of imaging to
longitudinal cognitive trajectories to measure the impact of CKD on brain changes, b)
including the entire range of CKD enriched with advanced CKD, and c) applying a
multidisciplinary approach. Our work is significant because it will inform the natural
history of cognitive decline and associated brain pathology in CKD and their contributors. It
will have impact by 1) identifying CKD patients at greatest risk for CI to alert clinicians,
and the timing of potential interventions, 2) measuring the effect of high phosphorus and
anemia on cognitive decline and brain changes, and 3) characterizing vascular and Alzheimer's
disease brain changes in CKD.
METHODS Study Population Approximately 225 remaining BRINK CKD participants (eGFR < 60; mean
eGFR 34) using the CKD-EPI creatinine equation) and 100 age and race matched non-CKD patients
with Stages 3-5 CKD (ages 50 and older will be followed in-person, by telephone, or by
medical records at the following locations: Hennepin Healthcare clinics, HealthPartners
clinics, the University of Minnesota - Fairview Clinics, and/or the Minneapolis Veterans
Affairs Medical Center (MVAMC).
Study Measures
1. A screening interview will be conducted via telephone to determine eligibility (using
criteria listed below) to continue to participate in BRINK 2.0 when scheduling the first
visit.
2. All BRINK 2.0 participants will continue to be classified as CKD (GFR < 60
ml/min/1.73m2) or non- CKD controls (eGFR ≥ 60 ± 5 ml/min/1.73 m2) based on their
initial classification at their baseline visit.
3. At the initial and three subsequent annual face-to-face visits, the medical history
interview and questionnaires, cognitive testing, and physical function assessment will
take approximately 75-90 minutes.
4. If the participant scores < 78 on 3MSE or < 18 on MOCA, an informant interview is
triggered either in-person or by telephone to assess the participant's risk of MCI or
dementia. The informant interview will be conducted with the Functional Assessment
Questionnaire (FAQ) instrument. If no informant is available, conduct the UPSA
performance-based assessment with the participant at the same time as current visit.
5. A structured telephone interview will be conducted at intervening six months with brief
questionnaires.
6. If the participant has missed their last annual visit, the participant will be scheduled
for a face-to-face visit at six months ± two months from their last scheduled annual
visit with cognitive battery two (from previous six month visits, and using MOCA instead
of 3MS).
7. If a participant is unable to attend an annual face to face visit, the TICS cognitive
phone test will be conducted within ± 2 months instead of their scheduled face-to-face
annual visit.
8. If the participant initiates any modality of dialysis, or undergoes renal transplant, a
follow-up visit will be scheduled as soon as possible. The participant will then
continue to be seen at six month intervals from the initial post dialysis visit. For the
dialysis or transplant patients, at 6, 18, and 30 month follow-up visits, a person
identified as the participant's informant will be interviewed with the ADCS- IADL to
assess the participant's functional status and dementia status.
9. For the subset of non-dialysis / transplant subjects who received a baseline MRI, a
three year and five year follow-up MRI will be obtained if still within their three
month window from previous respective annual visit. If a participant has missed their 3
year and/or 5 year MRI, additional MRIs should be obtained following their 4th, 6th,
7th, or 8th year visit in order to obtain a total of a maximum of three MRIs. Follow up
MRIs need to be completed with a two year gap in-between each MRI.
10. An MRI will also be obtained within 90 days after dialysis initiation and then at 1 year
and annually thereafter for a maximum of 5 MRI's after dialysis initiation, each with a
90 day window from their in person visit..
11. Laboratory measures: renal panel (sodium, potassium, chloride, carbon dioxide, anion
gap, albumin, calcium, creatinine, phosphorus, glucose, blood urea nitrogen, eGFR),
hemoglobin, hemoglobin A1c, urine albumin, urine microalbumin/creatinine ratio,
creatinine, and lipid panel will be collected at baseline and annually.
12. Research biomarker labs: serum and plasma for cystatin C, IL-6 in serum, IL-6 in urine,
TNFα receptor-1, 8-isoprostane, parathyroid hormone, 25-OH vitamin D, advanced glycation
end products, clusterin, asymmetric dimethylarginine (ADMA). were obtained at baseline
BRINK 1 visit, and at the 3 year annual visit, or if missed then, at the next in- person
BRINK 2 visit. If research labs are unable to be obtained during the first BRINK 2.0 in
person visit, the sample will be collected at the next annual in person visit.
